Latest / "Isn't That Interesting?!": Breast Cancer Survivor Stories + Remarkable Research / Season 4 / Episode 6: Dr. Norberto Zwirner
Transcript
- 0:00Cancer may try to run, but it cannot hide, leaving behind
- 0:03molecular crumbs that researchers have been trying to
- 0:07detect for decades. An Argentinian biochemist may
- 0:11have found a way to spot one of them, a molecule found on tumor
- 0:15cells but not normal tissue. With support from earlier.org,
- 0:19this research could lead to an earlier, minimally invasive
- 0:23cancer detection and treatment. Here's Martha Kaley, founder and
- 0:28executive directorofearlier.org with this episode of Isn't That
- 0:32Interesting? Welcome.
- 0:34And this is another wonderful researcher.
- 0:37And you might recognize that he's not from from the South.
- 0:42He's maybe just a little bit different his he's from
- 0:45Argentina. And so I'm so excited to be able
- 0:47to have a conversation with him. And it's Doctor Roberto
- 0:52Sablener. I kind of murdered that, but
- 0:55that was pretty close, right? Yeah.
- 0:58OK. So we're just going to start and
- 1:01let him explain what he his research is is looking at.
- 1:06And we awarded him funding in 2024, I believe.
- 1:10So. So that's where just go ahead
- 1:13and tell us about the the thing that you're looking for.
- 1:16And I know I want to say before we do that, I want to say that
- 1:20as Lerner is very noted for his this work that he is involved in
- 1:27and is one of the probably correct me if I'm wrong, I think
- 1:31it's one of the smaller, the least researched approaches
- 1:36until now with your new technology.
- 1:39So. So I'll let you go ahead and
- 1:41start to give us a definition of what it's all about.
- 1:44OK. Thank you very much.
- 1:45First of all, I want to acknowledge earlier.org for this
- 1:49support and this opportunity. Indeed, the story of our lab
- 1:53started nearly 3 decades ago when I established my lab in
- 1:58Argentina after postdoc of more than three years in the US in
- 2:02Dallas. And at that time, the work
- 2:05focused on in cases and one particular molecule which is
- 2:08called MICA. MICA which is a ligand for one
- 2:14of the receptor that activates in cases whose name is NKG 2D.
- 2:19At that time, we learned that tumors express Nikkei and normal
- 2:23tissues do not. So this is a molecule that is on
- 2:26the surface of the tumors, making it an attractive
- 2:28candidate to be targeted with antibodies, with monoclonal
- 2:32antibodies. And that is one of the research
- 2:35lines we have in the lab. But also at the time we learned
- 2:39that tumors can shed Nikkei. They just cut it from the
- 2:43surface and release it. And that soluble form of Mikkei
- 2:48can be detected in the in the serum, in the plasma of of tumor
- 2:53patients with different types of tumors, cancer patients.
- 2:57What is the role of this soluble Mikkei?
- 2:59While this soluble Mikkei binds to NKC 2D to encases and
- 3:03disables this, so it participates in tumor immune
- 3:08escape, favors the tumor growth in the patient.
- 3:11So that that dual role of Mikkei on one side when expressed on
- 3:16the surface of the tumor cells as a target for immune
- 3:19surveillance and when it is released as soluble Mikkei and
- 3:24participates in human escape convince us that measuring
- 3:28soluble Mikkei in blood of patients could be a useful
- 3:31biomarker. The problem that we have is that
- 3:34existing assets at that time mainly ELISA assays were not
- 3:40sensitive or reliable enough in complex samples like serum or
- 3:44plasma. So there was a real need to
- 3:46develop novel methods. And a few years ago we decided
- 3:51to build something better, which is FRET based immunoassay.
- 3:56In particular, we focused on breast cancer because Mikkei
- 4:01soluble Mikkei is highly expressed in in in these
- 4:04patients and because there was a real admit need for better
- 4:08minimal invasive nearly detection tools.
- 4:11Right. So, so talk about please what
- 4:14you actually how you amplified your study with that.
- 4:18I think it's so interesting when I was reading your work about
- 4:22the complexity of defining that within plasma and because it
- 4:29there's so much interference. But the but the important part
- 4:32about this, I think it's so interesting that it's from the
- 4:36cancer cells that that impact the natural killer cells right
- 4:41in the immune system and kind of shut, shut that down more so.
- 4:46So if you'll go ahead and just tell us about maybe in the
- 4:50simplest terms you can so that I can understand it about the the
- 4:54how you amplify the technology so that there can use it with
- 4:59smaller amounts of of cells. Yeah.
- 5:02Well the technology that we developed as I I mentioned
- 5:06before is a Fred based immunoassay.
- 5:08We call it Fredia Fred based immunoassay.
- 5:11Fred stands for First Term Resonance Energy Transfer And
- 5:16what we do in our assay, we design it to use two fluorescent
- 5:20types, one is Europium and one is Aloficocianin that produce
- 5:25measurable signals when brought very close together in in the
- 5:30plate where we run the assay. So in our setting that only
- 5:35happens in the presence of soluble micae.
- 5:38So in samples in which you don't have soluble micae, you cannot
- 5:41detect fluorescence and in samples that you where you have
- 5:45soluble micae you detect such fluorescence.
- 5:47And there is a correlation between the amount of soluble
- 5:52megae in the samples, in this case the plasma or or the serum
- 5:56of the patients and the intensity, the amount of
- 5:58fluorescence. So what we do is we capture
- 6:02soluble megae between two anti megae antibodies.
- 6:06One of these antibodies has a biotin tag and then this biotin
- 6:11is detected by streptavidin, which is a protein that binds
- 6:15specifically to biotin. And this stratabine is tagged
- 6:19with Europium. And then we have a specially
- 6:22designed buffer which contains APC aloficozanine.
- 6:26And so you have all the components in the system.
- 6:30You have captured soluble migay, the biotin detected by a
- 6:33stratabine that has the European tag and the ABC aloficozanine
- 6:40and that completes the energy transfer process, giving a
- 6:43glowing signals that we can quantify in a fluorometer.
- 6:47And this results in a very clean sensitive readout signal.
- 6:52In practical terms, this lets us detect solubility down to about
- 6:5710 picograms per ML of of plasma using only a very small amount
- 7:03of sample. Let's say with less than 50
- 7:05microliters of plasma, we have enough to run the assay in
- 7:11triplicate. So this the detection of 10
- 7:16pipograms per ML is roughly is much more sensitive than the
- 7:22about 60 pipograms per ML that other commercial kits can
- 7:28detect. So this aspect is very important
- 7:32because soluble Miguel circulates at low concentrations
- 7:36especially at early phases of the disease.
- 7:39So in our more sensitive assay can catch signals that
- 7:44conventional methods would miss exactly what you need for early
- 7:49detection. And also this allows us to track
- 7:52changes during treatment to see if a patient is responding or
- 7:55not to the treatment right in a shrinkage in of the tumor and
- 8:01less production of SOLU MIC a. Right.
- 8:05So, so you can kind of follow the treatment to see and there
- 8:10is less production of the soluble MIC a then that when
- 8:15when the treatments being successful, correct.
- 8:17Yeah, that is of course we have several aspects that we still
- 8:23need to test because what we have in ESA is that the Sermor
- 8:28plasma in which the Solviga is present, this this is the the
- 8:33liquid biopsy, the biological samples that can be easily taken
- 8:37from patient. These, these matrixes are very
- 8:41complex and crowded environments full of protein and lipids and
- 8:44that that usually interfere with antibody detection of rares and
- 8:48signals. So the the test that we
- 8:50developed after testing several configurations and using known
- 8:56amounts of recombinant Nikkei let us to identify conditions in
- 9:00which we we almost had no matrix interference while preserving
- 9:06the sensitivity, which is a clear step forward for this kind
- 9:10of complex samples. What we have we started the
- 9:14study with real samples from patients and we there got a
- 9:18small cohort of of samples and could observe that or measured
- 9:23soluble became plasma from healthy donors as a control of
- 9:27course from her 2 positive and her two negative breast cancer
- 9:31patients. And we saw clearly elevated
- 9:34levels in patients with interesting differences between
- 9:38subtypes. Also in a in in a small cohort
- 9:42of paired samples before and after treatment.
- 9:44It means the same patient sample taken before the treatment and
- 9:47sample taken after the treatment.
- 9:49We observed that soluble migay shifted with the therapy.
- 9:52So this suggests that the method is also useful for monitoring
- 9:58treatment response. So the most realistic near term
- 10:02application is as a companion biomarker for diagnostic
- 10:07patients helping inform the treatment decisions for a
- 10:11physician, for an oncologist. And also we don't forget we have
- 10:16very present the early detection which vision which is of course
- 10:20exactly the focusofearlier.org, which is also one of our
- 10:25ultimate goals screening healthy or at risk women before a tumor
- 10:30is clinical clinically detectable.
- 10:33But this is more complicated task because it it requires
- 10:37larger cohorts including women without cancer and also a close
- 10:42follow up to take cancer at very early stages.
- 10:45And this is our next challenge. Of course that will take
- 10:49several, several years because of as I mentioned, we need to
- 10:52follow up the patients to see if they develop or or or not a
- 10:55tumor. So that is another different
- 10:59challenge. But it's a great challenge and
- 11:01I'm so happy. That.
- 11:03I'm so happy that you have approached it the way that you
- 11:08have and you've, you've recognized so many things.
- 11:11And I just think this anytime we can get the biomarkers is just
- 11:16such a critical component for for us and for the public.
- 11:21How so? How long do you think that the
- 11:24process will will take to actually, I know we in the
- 11:30information I was reading you were talking about hoping that
- 11:34you could involve like a startup, startup company or
- 11:38something like that to produce those to produce kits for, for
- 11:42the physicians. Is that how would that help you?
- 11:46Yeah. Well, yeah, it's true.
- 11:50We have several options to to to advance the the system. 1 is to
- 11:57to. First of all, we need to
- 11:59validate the the performance of the of the system of the kit to
- 12:04detect soluble Nikkei in in a larger cohort of patients.
- 12:09That will allow us to to think of the possibility of developing
- 12:13a commercial kit. We have several earlier options
- 12:16which is to build a dedicated service facility.
- 12:20We can that very easily and that would imply that the health
- 12:28institutions just send us the plasma or from the patients and
- 12:32we measure it in our institute. That is the first and most easy
- 12:38option. Of course we are very interested
- 12:41in licensing the technology or partnering with a startup
- 12:46company. We already have had
- 12:48conversations with a startup established in in Argentina that
- 12:53is developing another methods to follow up cancer patients with
- 12:57focus on, on breast cancer and lung cancer.
- 13:01And they are very interested in in our method.
- 13:04So as long as they can secure funds, they probably will open a
- 13:10new pipeline with our method. But for this, we need to
- 13:14consolidate ourselves with a larger court of patience.
- 13:17As I mentioned, of course, the, the, the other possibilities to,
- 13:21to create a startup by ourselves and all these possibilities that
- 13:27they mentioned are in, in our on, on our desk and we need to
- 13:31decide which is the best one. But we, what we are convinced is
- 13:36that we want to bring this to the patient.
- 13:38We don't want that this is knowledge generated in a lab and
- 13:41that stays in a lab without a benefit for the patient.
- 13:46We want to move to to do something that can apply to real
- 13:51patients and to help to take decisions.
- 13:54And which I really appreciate. All right, that's one of the
- 13:57things I like for our audience to realize is that researchers
- 14:03are not just in research they're they're really working toward an
- 14:09end and I'm looking at the different studies through
- 14:12biomarkers. I think that this is this is
- 14:15what I feel like it's just really the critical component.
- 14:19I know when you were we were discussing the the the benefits
- 14:24of what the grant. Tell me about your student who
- 14:29got her BS because through this. Yeah, Yeah.
- 14:34We took the opportunity with this funding and it was
- 14:37something that was sort of a closed project and we say, OK,
- 14:41why not to hire to to incorporate a student for
- 14:46undergrad thesis and that's what we did.
- 14:48So we took the opportunity of this brand from the org not only
- 14:53to develop the method on all what I explained and also to,
- 14:56to, to train human resources and to, to, to work on, on the
- 15:02scientific system to, to, to generate repair people.
- 15:06So that is also another benefit that that we obtained from this.
- 15:13Sorry, we are close to the window.
- 15:15OK, No. It's OK.
- 15:18So another thing I I would like to mention is we have several
- 15:23unanticipated benefits from our because we did only, we not only
- 15:30screened serum or plasma from patients, we also tried to
- 15:35detect soluble Micae in cell cultural supernatants in the, we
- 15:39cultural cell lines from different tumor types and assess
- 15:43soluble Micaean the cell cultural supernatants.
- 15:46And what we observed is that our method can detect soluble Nikkei
- 15:50without concentration of the sample, something that
- 15:53commercial lysis can't, not, can't do really reliably.
- 15:57So the method works better than commercial lysis.
- 16:01And this is very important because this opens the door for
- 16:05screening to screen candidate drugs and antibodies and how
- 16:10they affect Nikkei shaving the production of soluble Nikkei
- 16:13from tumor cells. So this is a very valuable tool
- 16:17for early stage drug discovery, which is something that in in in
- 16:22the industry, in the biopharma industry is, is a very
- 16:25attractive field in these days. That that's just amplifies two
- 16:33things to me. One is that you're generating
- 16:36new researchers with extra knowledge and the fact that
- 16:41you're able to expand and amplify this work along with
- 16:47that. So it, it's, I think it's just
- 16:50very promising work that you've been doing.
- 16:53And I'm, I'm looking forward to following even more for, for
- 16:57what you're able to accomplish, but but you've done just amazing
- 17:03work and, and I think it's coming to fruition for you to
- 17:07see that. And, and I thank you so much for
- 17:10helping us understand a little bit better the fact that we're
- 17:16approaching earlier detection in number of different directions.
- 17:20So it's, it's not going to be able to slip out of the future.
- 17:24I don't think. So is there any particular that
- 17:28you would like to share with our audience or any support that
- 17:32researchers might need or can you just address that for us?
- 17:37Yeah. I would like to mention also
- 17:39that that we observed we applied this method of course with the
- 17:44primary focus of breast cancer, but we also tested plasma on
- 17:49serum from other types of cancers including TR cell renal
- 17:53cell carcinoma is 1 the most common kidney cancer and we have
- 17:58also a huge amount of plasma from lung cancer patients.
- 18:03So in the case of a small cohort of of kidney cancers and also
- 18:09pancreas cancer, we observed that we can also detect SOLU
- 18:13negating in in plasma from these patients.
- 18:16So it means that that the, the method is will we expect that
- 18:21the metal will not only be useful for breast cancer
- 18:24detection and follow up, but also for other types of cancer.
- 18:28This broadens the, the application platform, the
- 18:31application spectrum of the platform.
- 18:34And so the, the I, I feel, I am very, very thankful to
- 18:42earlier.org. I feel that although the project
- 18:45had a formal end date, we keep working on this development
- 18:50because we feel that we can provide novel assets to improve
- 18:53the diagnosis and follow up measuring very attractive
- 18:57biomarker with primary focus on breast cancer, but also in other
- 19:02types of cancer, as I mentioned, in this way to contribute to the
- 19:05improvement of Women's Health in the case of breast cancer or
- 19:09other types of cancer too. And of course, we are very
- 19:15thankful to earlier.org for the support, which it was absolutely
- 19:21critical to to start with this project and to, to allow us to,
- 19:28to develop this, this method. Well, I just am so appreciative
- 19:32of your sharing your time with us.
- 19:34That's very, you're very kind to do that because this is just one
- 19:39of the things it's hard to as a layperson, it is difficult to
- 19:44understand, but I feel like that cancer is not being able to slip
- 19:49by us anymore. We're, I think we're on the
- 19:52right tracks for and just like you said, to crossover to be
- 19:57useful in other cancers too. So thank you for your work.
- 20:01It's been lovely chatting with you and I really appreciate
- 20:05staying, staying up to what you're doing.
- 20:07It's very, it's very exciting. Thank you and thank you all of
- 20:12you earlier or you do an amazing work and we are witnesses of
- 20:17that work. Well, thank you so much and good
- 20:19luck to your protege there that you have read just with her.
- 20:23OK. Thank you very much all.
- 20:26Right, bye. Bye, bye, bye.
- 20:28This episode of Isn't That Interesting was made possible
- 20:32thanks to volunteers and donors just like you.
- 20:34It was hosted by Martha Kaley, founderofearlier.org and edited
- 20:39by Liam Mcburney. I'm Valerie Amsterdam, reminding
- 20:42you that for the last 30 years, this is North Carolina based
- 20:45organization has helped fund groundbreaking research all over
- 20:49the world, from molecular imaging to a sensitive blood
- 20:53test for breast cancer. Plain and simple, earlier
- 20:56detection saves lives. And you can help host a
- 20:59fundraising event, make a donation or volunteer your time.
- 21:03You can find us not only on the web, but on Facebook and
- 21:06Instagram too. Let's change the picture of
- 21:08breast cancer together.